Volume 20, Number 5—May 2014
Research
Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
Table 3
Human papillomavirus prevalence in oropharyngeal squamous cell carcinomas, select United States registries, 1995–2005*
Variable | No. (%) cases, N = 557 |
---|---|
Characteristic | |
HPV (any type) | 403 (72.4) |
High risk† | 396 (71.1) |
Low risk‡ | 7 (1.3) |
Negative | 154 (27.6) |
Single type | 381 (68.4) |
Multiple types§ |
22 (3.9) |
Type | |
HPV-16 | 337 (60.5) |
HPV-33 | 31 (5.6) |
HPV-18 | 14 (2.5) |
HPV-35 | 11 (2.0) |
HPV-39 | 5 (0.9) |
HPV-31 | 4 (0.7) |
HPV-52 | 4 (0.7) |
HPV-45 | 3 (0.5) |
Other HPV types | 16 (2.9) |
*HPV, human papillomavirus; high risk, virus type is associated with high oncogenic potential; low risk, virus type is associated with low oncogenic potential.
†Positive for any of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
‡Positive for types other than those identified as high risk.
§HPV-16/-33 (6 cases), HPV-16/-18 (3 cases), and HPV-16/-31(3 cases).
1Members of HPV Typing of Cancers Workgroup who contributed to this study are listed at the end of this article.
Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.